Keyphrases
Myelofibrosis
100%
Anti-PD-1
100%
Anticancer Immune Response
40%
Disease Pathogenesis
40%
Programmed Death-ligand 1 (PD-L1)
40%
Constitutional Symptoms
20%
Lymphocyte Subsets
20%
JAK-STAT
20%
Cytopenia
20%
Refractory Solid Tumors
20%
Symptomatic Improvement
20%
Cytokine Milieu
20%
JAK Inhibitors
20%
Tolerability
20%
Change of Measure
20%
Anti-tumor Response
20%
Innovative Approach
20%
Tumor Malignancy
20%
PD-L1 Expression
20%
Patients with Cancer
20%
Extramedullary Hematopoiesis
20%
Dysregulation
20%
Lymphoid Malignancies
20%
Bone Marrow
20%
Novel Therapeutics
20%
Disease Phenotype
20%
Overall Survival
20%
Antagonism
20%
Life Expectancy
20%
Leukemic Transformation
20%
Inflammatory State
20%
Medicine and Dentistry
Myelofibrosis
100%
Cytokine
40%
Immune Response
40%
Malignant Neoplasm
40%
Diseases
40%
Lymphocyte Subpopulation
20%
Cytopenia
20%
Life Expectancy
20%
Solid Malignant Neoplasm
20%
Janus Kinase Inhibitor
20%
Neoplasm
20%
Constitutional Symptoms
20%
Overall Survival
20%
Extramedullary Hematopoiesis
20%
Pharmacology, Toxicology and Pharmaceutical Science
Myelofibrosis
100%
Malignant Neoplasm
60%
Cytokine
40%
Diseases
40%
Overall Survival
20%
Tolerability
20%
Life Expectancy
20%
Solid Malignant Neoplasm
20%
Janus Kinase Inhibitor
20%
Neoplasm
20%
Cytopenia
20%